Affordable Access

Access to the full text

Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

Authors
  • Saadati, Saeede
  • Sadeghi, Amir
  • Mansour, Asieh
  • Yari, Zahra
  • Poustchi, Hossein
  • Hedayati, Mehdi
  • Hatami, Behzad
  • Hekmatdoost, Azita
Type
Published Article
Journal
BMC Gastroenterology
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jul 25, 2019
Volume
19
Issue
1
Identifiers
DOI: 10.1186/s12876-019-1055-4
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundThe aim of the present study was to evaluate the effects of curcumin supplementation on inflammatory indices, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD).MethodsFifty patients with NAFLD were randomized to receive lifestyle modification advice plus either 1500 mg curcumin or the same amount of placebo for 12 weeks.ResultsCurcumin supplementation was associated with significant decrease in hepatic fibrosis (p < 0.001), and nuclear factor-kappa B activity (p < 0.05) as compared with the baseline. Hepatic steatosis and serum level of liver enzymes, and tumor necrosis-α (TNF-α) significantly reduced in both groups (p < 0.05). None of the changes were significantly different between two groups.ConclusionOur results indicated that curcumin supplementation plus lifestyle modification is not superior to lifestyle modification alone in amelioration of inflammation.Trial registrationIRCT20100524004010N24, this trial was retrospectively registered on May 14, 2018.

Report this publication

Statistics

Seen <100 times